About tafasitama b
Anti-CD19 monoclonal antibody
Used for
- With lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem-cell transplant.
Usual adult dose
12 mg/kg intravenously on days 1, 8, 15, and 22 of cycles 1–3; days 1 and 15 of cycles 4–12, with lenalidomide. Thereafter, every two weeks until progression or unacceptable toxicity.
Common side effects
- Infusion reactions
- Low blood-cell counts, including neutropenia and thrombocytopenia
- Infections
- Fatigue, diarrhea, or cough
Important warnings
- Infusion reactions can be serious; monitoring and premedication are required.
- Can cause severe or prolonged low blood-cell counts and infections.
- Hepatitis B may reactivate; screening and monitoring are needed.
- Treatment should be managed by clinicians experienced in cancer therapy.
Pregnancy
May harm an unborn baby; pregnancy should be avoided during treatment and for at least three months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least three months after the last dose.
Interactions
- No clinically significant drug interactions are established; lenalidomide is given with tafasitamab for the indicated lymphoma treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.